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Introduction
VEGF-A is a potent angiogenic factor that stimulates vascu-
lar endothelial cell survival, proliferation, migration, and dif-
ferentiation, alters their pattern of gene expression, and delays 
senescence (Dvorak, 2000). VEGF acts through binding to 
VEGF receptor 1 (VEGF-R1; fl  t-1) and 2 (VEGF-R2; KDR/fl  k-1), 
the latter apparently mediating most of the VEGF signaling, 
whereas the role of VEGF-R1 is more elusive (Waltenberger et al., 
1994). Affi  nity binding of VEGF-A to VEGF-R2 is enhanced by 
neuropilin-1, a nonkinase coreceptor (Soker et al., 1998).
Both homozygous and heterozygous deletions of the 
VEGF-A gene in mice are embryonic lethal (Carmeliet et al., 
1996; Ferrara et al., 1996), suggesting that a fi  nely tuned regula-
tion of VEGF expression is essential for development. Excessive 
and/or ectopic angiogenesis or its reverse, defective vascular-
ization, is responsible for several pathologies. VEGF is a major 
initiator of tumor angiogenesis, a critical step in cancer growth 
and metastasis (Skobe et al., 1997). Overexpression of VEGF 
is also determinant in retinopathies (Caldwell et al., 2005) and 
many other diseases. A large effort is being produced to decrease 
the excessive production of VEGF or to tackle VEGF-induced 
angiogenesis with neutralizing antibodies, antagonists, function 
inhibitors, or inhibitory soluble receptors (Ferrara, 2005). In con-
trast, pathologies such as ischemia, chronic wounds, and erec-
tile dysfunction could benefi  t from neovascularization driven by 
VEGF delivery (Lauer et al., 2002; Yoon et al., 2004; Burchardt 
et al., 2005).
VEGF is a disulfi  de-bonded dimeric glycoprotein with a 
molecular mass of 34–45 kD encoded by a gene that contains 
eight exons. The known isoforms of human VEGF generated by 
alternative splicing are encoded by exons 1–5 and a varying com-
bination of the other exons (Jingjing et al., 1999; Whittle et al., 1999; 
Robinson and Stringer, 2001; Bates et al., 2002). The domains 
encoded by the fi  rst four exons contain the signal peptide, the 
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U
ltraviolet B and genotoxic drugs induce the ex-
pression of a vascular endothelial growth factor A 
(VEGF-A) splice variant (VEGF111) encoded by 
exons 1–4 and 8 in many cultured cells. Although not 
  detected in a series of normal human and mouse tissue, 
VEGF111 expression is induced in MCF-7 xenografts in 
nude mice upon treatment by camptothecin. The skipping 
of exons that contain proteolytic cleavage sites and extra-
cellular matrix–binding domains makes VEGF111 diffusible 
and resistant to proteolysis. Recombinant VEGF111 activates 
VEGF receptor 2 (VEGF-R2) and extracellularly regulated 
kinase 1/2 in human umbilical vascular endothelial cells 
and porcine aortic endothelial cells expressing VEGF-R2. 
The mitogenic and chemotactic activity and VEGF111’s 
ability to promote vascular network formation during 
  embyonic stem cell differentiation are similar to those 
of VEGF121 and 165. Tumors in nude mice formed 
by HEK293 cells expressing VEGF111 develop a more 
widespread network of numerous small vessels in the 
peri  tumoral tissue than those expressing other isoforms. 
Its potent angiogenic activity and remarkable resistance 
to proteolysis makes VEGF111 a potential adverse factor 
during chemotherapy but a beneﬁ  cial therapeutic tool for 
ischemic diseases.
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  sequence of recognition by VEGF-Rs, and a glycosylation site. 
The amino acid sequence encoded by exon 5 includes the main 
site of cleavage by plasmin (Claffey et al., 1995; Keyt et al., 1996) 
and matrix metalloproteinases (Lee et al., 2005). Exon 6 encodes 
the sequence that binds to heparin and a cell surface retention 
consensus sequence. The sequence encoded by exon 7, besides 
a moderate affi  nity for heparin and heparan sulfate proteoglycans, 
contains the binding site for neuropilin-1. VEGF121 (lacking 
exons 6 and 7) is freely diffusible, whereas VEGF189 (contain-
ing exons 1–6A, 7, and 8) is primarily associated with the cell 
surface and the ECM. VEGF165 (containing exons 1–5, 7, and 8) 
displays properties that are intermediate between VEGF189 and 
121 (Park et al., 1993).
Cancers often arise as a consequence of the accumula-
tion of genetic mutations induced by a wide variety of physical 
and chemical agents. UV irradiation is an environmental ele-
ment with carcinogenic potential. UV-B (290–320 nm) induces 
the formation of cyclobutane pyrimidine dimers in the DNA, 
which are considered to play an essential role in skin cancer 
induction (Katiyar et al., 2001). Cutaneous alterations observed 
after a single exposure to UV-B include erythema and edema 
related to an altered expression of biological mediators, includ-
ing angiogenic factors (Blaudschun et al., 2002). In this paper, 
we show that UV-B irradiation and genotoxic drugs induce the 
expression of a new VEGF splice variant, an isoform lacking 
the sequence encoded by exons 5–7. This isoform, which is bio-
logically active and resistant to proteolysis, may be of thera-
peutic interest.
Results
UV-B and genotoxic agents induce the 
expression of a new VEGF isoform lacking 
exons 5–7
UV-B irradiation (30 mJ/cm
2) of HaCat cells, MDA-MB-231 
cells, and MCF-7 cells affected the expression of the mRNA en-
coding the various VEGF isoforms as evaluated by quantitative 
RT-PCR. Using primers P1 and P2 (Table I; Hajitou et al., 2001) 
chosen on exons 3 and 8, respectively, VEGF189, 165, and 121 
mRNAs were detected in control and UV-exposed cells (Fig. 1 A, 
top left). Upon UV treatment, the mRNA levels of VEGF165 and, 
to a smaller extent, VEGF189 and 121 were decreased, whereas 
a faster migrating RT-PCR product (Fig. 1 A, arrows) was ob-
served in MCF-7 cells and, at a lower level, in HaCat and MDA-
MB-231 cells. This product was never observed in nonirradiated 
cells. Sequence analysis of this fast migrating product revealed 
the presence of sequences of exons 3, 4, and 8 and the absence of 
sequences encoded by exons 5–7. Sequencing of the full-length 
fast migrating VEGF cDNA variant amplifi  ed using primers 
P3 and P4 (GenBank/EMBL/DDBJ accession no. DQ229900; 
Table I) demonstrated that it was formed by exons 1–4 and 8. 
Skipping of the 30 bp encoded by exon 5 did not change the 
reading frame of the downstream sequence. According to the cur-
rent nomenclature, this new splice variant was named VEGF111, 
as the sequence theoretically encodes a 111 amino acid–long 
human VEGF molecule after excision of the signal peptide. It is 
noteworthy that the total VEGF mRNA level, which can be quanti-
tatively evaluated thanks to the synthetic RNA used as internal 
standard in each RT-PCR reaction tube, is only barely modifi  ed 
in the UV-treated cells. VEGF111 is formed mostly at the expense 
of the VEGF165 variant.
As the junction between exons 4 and 8 is specifi  c to 
VEGF111 mRNA, this isoform was specifi  cally RT-PCR ampli-
fi  ed by using a reverse primer (P5) sitting astride these exons, 
primer P1 being used as forward primer. A product of the 
  expected size (237 bp) was detected using RNA from UV-B–
irradiated cells but not from control cells (Fig. 1 A, middle left).
A dose-response analysis of the expression of VEGF111 
mRNA upon treatment with UV-B up to 30 mJ/cm
2 was per-
formed in MCF-7 cells. Data indicated that the expression of 
VEGF111 progressively increased with the energy of the irradi-
ation (Fig. 1 B). The level of VEGF111 mRNA reached  25% 
of the overall VEGF mRNA in the illustrated experiment but 
may vary between 25 and 40% from experiment to experiment. 
An energy of 30 mJ/cm
2 was chosen in all subsequent experi-
ments. A time-course relationship was also established in MCF-7 
cells. VEGF111 mRNA was readily detected 12 h after irradiation, 
peaked at 24 h, and decreased thereafter (Fig. 1 C). A cDNA 
Table I. The ampliﬁ  ed RNA, primer numbers, sequences, and length in base pairs of RT-PCR products
Primer mRNA Primers Length Std
bp bp
P1 (forward) 
P2 (reverse)
VEGF C  C  T  G  G  T  G  G  A  C  A  T  C  T  T  C  C  A  G  G  A  G  T  A   
C  T  C  A  C  C  G  C  C  T  C  G  G  C  T  T  G  T  C  A  C  A 
530, 479, 407, 
347, 275, 245
a
311
P3 (forward) 
P4 (reverse)
VEGF (full length) C  A  C  A  C  G  C  G  G  C  C  G  C  C  G  A  A  A  C  C  A  T  G  A  A  C  T  T  T  C  T  G  C  T  G  T  C   
A  C  A  C  A  G  C  T  A  G  C  T  C  A  C  C  G  C  C  T  C  G  G  C  T  T  G  T  C  A  C  A 
586, 454, 424
b NA
P1 (forward) 
P5 (reverse)
VEGF111 speciﬁ  cC   C  T  G  G  T  G  G  A  C  A  T  C  T  T  C  C  A  G  G  A  G  T  A   
C  T  C  G  G  C  T  T  G  T  C  A  C  A  T  C  T  G  C  A  T  T  C  A 
237 NA
P6 (forward) 
P7 (reverse)
28S rRNA G  T  T  C  A  C  C  C  A  C  T  A  A  T  A  G  G  G  A  A  C  G  T  G   
G  A  T  T  C  T  G  A  C  T  T  A  G  A  G  G  C  G  T  T  C  A  G  T 
212 269
P8 (forward) 
P9 (reverse)
Bcl-X A  C  C  C  C  C  A  G  T  G  C  C  A  T  C  A  A  T  G  G  C  A  A   
C  C  C  G  T  C  A  G  G  A  A  C  C  A  G  C  G  G  T  T  G  A 
512 (Bcl-Xl) 
324 (Bcl-Xs)
NA
P10 (forward) 
P11 (reverse)
CD31 C  A  A  G  G  C  G  A  T  T  G  T  A  G  C  C  A  C  C  T  C  C  A   
C  C  A  A  C  A  A  C  T  C  C  C  C  T  T  G  G  T  C  C  A  G  A 
206 NA
Std, length in base pairs of ampliﬁ  cation products of the synthetic standard RNA. NA, not available.
aFor humanVEGF206, 189, 165, 145, 121, and 111, respectively.
bFor human VEGF165, 121, and 111, respectively.INDUCTION OF VEGF111 BY GENOTOXIC AGENTS • MINEUR ET AL. 1263
corresponding to the VEGF111 amplifi  cation product was induced 
upon UV irradiation, although to various levels, in several human 
and animal cells lines and in primary human keratinocytes and 
fi  broblasts 24 h after treatment (Table II).
As UV-B is known to display genotoxic effects, the ex-
pression of VEGF111 was similarly investigated upon treatment 
with genotoxic agents inducing double-strand breaks, namely 
camptothecin, mimosin, and mitomycin C. 1 μM camptothecin, a 
DNA topoisomerase I poison, induced the expression of VEGF111 
in HaCat and MCF-7 cells within 24 h to a level similar or even 
higher than that observed after UV irradiation (Fig. 1 A). A dose-
response analysis indicated that VEGF111 induction progressively 
Figure 1.  Genotoxic agents induce the expression of VEGF111. The indicated cell lines were treated with 30 mJ/cm
2 UV-B, 1 μM camptothecin, 5 mM 
L-mimosin, or 100 μg/ml mitomycin C for 24 h except otherwise indicated, and VEGF mRNA, VEGF111 mRNA, and 28S rRNA were measured by RT-PCR. 
(A) PAGE analysis of RT-PCR products of VEGF mRNA (top), VEGF111 mRNA (middle), and 28S rRNA (bottom). Arrows in the top panel indicate the 
VEGF111 ampliﬁ  cation product. The drawings represent the exons (not to scale) encoding the corresponding VEGF isoforms. C, control cells; CPT, campto-
thecin treatment; M, 50-bp molecular weight markers; Mim, mimosin; MitC, mitomycin C; R, cells rinsed with red phenol–free medium but not irradiated; 
UV, UV-B irradiation; −, no cellular RNA. Asterisks indicate the RT-PCR products of synthetic RNA added to the test tubes to monitor reaction efﬁ  ciency. 
(B–E) Dose-response analysis (B and D) and kinetics of induction (C and E) of the VEGF111 mRNA level in MCF-7 cells irradiated by UV-B (B and C) or 
treated with camptothecin (D and E). VEGF111 mRNA is given in percentages of the total VEGF isoform mRNA. Error bars represent SD.JCB • VOLUME 179 • NUMBER 6 • 2007  1264
increased with the concentration of camptothecin in MCF-7 
cells (Fig. 1 D). Time-course analysis showed that VEGF111 
mRNA expression was already detected after 6 h and reached a 
plateau after 24 h (Fig. 1 E). MCF-7 cells treated with campto-
thecin for 24 h were washed and further incubated in fresh 
medium for up to 5 d. VEGF111 mRNA decreased rapidly after 
removal of the camptothecin, becoming undetectable after 24 h 
(unpublished data). 5 mM l-mimosin and 100 μg/ml mitomycin C, 
two other genotoxic agents, also induced the expres  sion of 
VEGF111 mRNA (Fig. 1 A, top right). A similar induction of 
VEGF111 was observed in MCF-7 cells treated by UV or camp-
tothecin in the absence of FCS in the medium. γ-Ray irradia  tion 
of some of these cell lines did not induce VEGF111 mRNA.
Mediums were conditioned for 24 h by MCF-7 cells either 
UV irradiated or treated with camptothecin for 6 h and were 
further washed to eliminate the compound. Naive MCF-7 cells 
incubated for 24 h with these conditioned mediums (CMs) did 
not express VEGF111 mRNA, suggesting that the induction 
of VEGF111 was not dependent on a paracrine mechanism 
(unpublished data).
Expression of VEGF111 in vivo
VEGF111 (or VEGF110, the equivalent of human VEGF111 in 
rodents) mRNA was measured by RT-PCR in a series of human 
and mice tissues as well as 6–18-d-old in toto mice embryos. 
No VEGF111/110 was detected in any of these tissues, whereas 
the traditional isoforms were easily detected, although at vari-
able levels. Trials to induce VEGF110 in healthy BalbC or nude 
mice upon UV-B, γ-ray irradiation, or i.v. injection of the geno-
toxic agent camptothecin or its water-soluble analogue irinotecan 
were not successful.
Nude mice supplemented with oestrogens received a sub-
cutaneous injection of MCF-7 cells (4 × 10
6 cells) mixed with 
100 μl matrigel on both fl  anks as previously described (Sounni 
et al., 2002). After 3 wk, tumors had developed, and mice were 
treated with a daily intratumoral injection of 50 μl camptothecin 
(2 mg/ml) in one fl  ank or the vehicle alone in the other fl  ank for 
1, 2, or 3 d and killed the day after the last injection. VEGF111 
mRNA was detected in tumors injected with camptothecin but 
not or to a barely detectable level in the tumors injected with the 
vehicle in the controlateral fl  ank (Fig. 2). No VEGF111 mRNA 
was detected in the tumors of noninjected mice while the other 
isoforms of VEGF were present.
Recombinant VEGF111 is glycosylated
Recombinant VEGF (reVEGF) 165, 121, and 111 were pro-
duced in serum-free medium of transfected HEK293 cells and 
thereafter were called reVEGFs (produced in eukaryotic cells). 
These cells were selected for their low intrinsic expression of 
VEGF. When evaluated in parallel cultures, the production of 
reVEGF by transfected HEK293 was always similar for VEGF121 
and 165 and threefold lower for VEGF111. CM containing 20 ng 
reVEGF, as measured by ELISA, were analyzed by Western 
blotting in reducing conditions with or without treatment with 
PNGase F (Fig. 3 A). In the absence of enzymatic treatment, 
VEGF appeared as a single band at  18 kD in the CM of HEK293 
expressing reVEGF111 and as a doublet at  17 and 21 kD and 
at 22 and 26 kD in the CM of HEK293 expressing reVEGF121 
and reVEGF165, respectively. No signal was detected in CM from 
cells transfected with the empty plasmid (unpublished data). 
As VEGF contains one glycosylation site, the bands of lower 
mobility likely correspond to glycosylated forms of reVEGF121 
and 165. They are indeed shifted to faster migrating forms at the 
expected size after deglycosylation with PNGase F. The deglyco-
sylated reVEGF165 produced in HEK293 cells displayed a mo-
bility identical to commercial reVEGF165 produced in bacteria. 
The reVEGF111 expressed as an 18-kD band was processed to 
the expected lower size ( 14 kD) upon PNGase F treatment, 
suggesting that the majority of reVEGF111 molecules are glyco-
sylated in HEK293 cells.
reVEGF111 is biologically active in vitro
Biological effects of reVEGF111 were evaluated in vitro on 
endothelial cells, human umbilical vascular endothelial cells 
(HUVECs), and porcine aortic endothelial cells (PAECs) express-
ing VEGF-R1 (PAEC/R1) or VEGF-R2 (PAEC/R2) or transformed 
with empty vector (PAEC; Waltenberger et al., 1994). reVEGF121 
and 165 were used as positive controls, and the CM of HEK293 
cells transfected with the empty vector was used as a negative 
control. HUVEC, PAEC, PAEC/R1, or PAEC/R2 starved over-
night were treated for 5 min with each of the three reVEGF 
  isoforms and the control CM. reVEGF111 was able to induce 
VEGF-R2 phosphorylation in HUVECs and PAEC/R2 at a level 
Table II. Induction of VEGF111 and Bcl-Xs/Bcl-Xl ratio by UV-B
Cells VEGF111 Bcl-Xs/Bcl-Xl
%
MCF-7 33 3.1
HuH7 26 ND
A2058 20 1.4
MO59K 16 1.4
HCT116 15 1.8
HT1080 14 0.7
BT549 12 0.9
AT5BIVA 12 ND
CHO 11 2.3
ES CGR8 8 ND
HUVEC 8 ND
PAM212 8 1.4
MEF 7 ND
HS578T 7 3.9
HaCat 6 1.7
HSF2 5 ND
HSF1 4 4.0
Human 
 keratinocytes
1–4 ND
HEK293 3 0.6
AT5BI 2 3.3
HeLa 2 2.5
MDA-MB-231 2 1.3
COS-1 0 2.1
NIH3T3 0 0.1
CT-26 0 ND
B16F10 0 ND
Percentage of VEGF111 (VEGF110 in rodent cell lines) mRNA over total VEGF 
mRNA and fold induction of the Bcl-X/Bcl-Xl ratio after UV-B treatment.INDUCTION OF VEGF111 BY GENOTOXIC AGENTS • MINEUR ET AL. 1265
similar to that induced by commercially available VEGF165, 
reVEGF165, and reVEGF121 (Fig. 3 B). Control medium had 
no effect. In contrast, we did not observe any phosphorylation 
of the VEGF-R1 in HUVECs or PAEC/R1. The phosphorylation 
of extracellularly regulated kinase 1/2 (ERK1/2) was induced in 
HUVECs, PAEC/R1, and PAEC/R2 but not in PAEC upon treat-
ment with reVEGF111, similar to reVEGF121 or 165 (Fig. 3 C). 
Control CM had no effect on the ERK1/2 phosphorylation 
  status. Together, these data indicate that VEGF111 signaling is 
mediated through VEGF-R1 and -R2.
The induction of intracellular calcium transients by 
reVEGF111 was investigated in HUVECs by single-cell real-time 
fl  uorescence microscopy. Although control medium induced 
calcium transients in only 15% of the cells, reVEGF111 induced 
calcium transients in 70% of them (i.e., to a level similar to that 
observed with reVEGF165 and 121; Fig. 3 D). reVEGF111 stimu-
lated HUVEC proliferation to the same extent as reVEGF121 
(twofold) and slightly less than reVEGF165 (2.5-fold; Fig. 3 E). 
Control CM induced a signifi  cantly lower cell proliferation rate.
PAEC/R2 cells and monocytes have been previously shown 
to migrate in response to a chemotactic gradient of VEGF165 
(Waltenberger et al., 1994; Stadler et al., 2007). We tested VEGF111 
for its ability to promote the migration of PAEC/R2 cells by us-
ing a modifi  ed Boyden chamber assay (Fig. 3 F). The strongest 
migratory response to VEGF111 was observed at concentrations 
ranging between 1 and 20 ng/ml with a peak at 10 ng/ml (20.8 ± 
2.3 cells/high-power fi  eld; P = 0.006 vs. unstimulated migration). 
The peak migration of PAEC/R2 cells to VEGF111 was slightly 
lower than the peak migratory response to VEGF165 (28.7 ± 
2.7 cell/high-power fi  eld peak migration; P = 0.09). In con-
trast, VEGF111-induced migration reached higher levels than 
that induced by VEGF121 (15.5 ± 1.7 cells/high-power fi  eld; 
P = 0.13). As tested by checkerboard analysis, the migration 
induced by VEGF111 occurred in the presence of a positive 
concentration gradient between the two compartments, indicat-
ing a true chemotactic activity without appreciable unspecifi  c 
chemokinetic activity. It is well established that monocytes iso-
lated from peripheral blood migrate in response to the activation 
of VEGF-R1, whereas the expression of VEGF-R2 is absent 
or below the detection limit (unpublished data). In our hands, 
VEGF111 showed no consistent effect on monocyte migration 
(unpublished data). These observations strongly suggest that 
VEGF111 mediates its chemotactic signal via VEGF-R2 rather 
than VEGF-R1.
VEGF111 induces an angiogenic phenotype 
in embryoid bodies
The proangiogenic activity of VEGF111 was tested in an embryoid 
bodies assay. Mouse embyonic stem cells were cultured for 6 d 
in the presence of the three reVEGF isoforms or the control 
medium. Embryoid bodies were fi  xed at day 6 and labeled by anti-
CD31 antibodies to visualize vascular structures. The density of 
the capillary-like structures was increased in the samples treated 
with the three reVEGF isoforms as compared with the control 
(Fig. 4 A) and evaluated by a visual score (Fig. 4 B). reVEGF111 
signifi  cantly increased the CD31 mRNA at day 4 (Fig. 4 C) to a 
level similar to that induced by reVEGF165 and 121.
To gain further insights into the mechanism of angiogenesis, 
the effect of the various reVEGF on the pattern of endothelial 
cell divisions in embryoid bodies was undertaken according to 
the procedure described by Zeng et al. (2007). Embryoid bodies 
were prepared and supplemented with 5 ng/ml reVEGF111, 
121, or 165. At day 8, they were fi  xed and immunostained with 
anti-CD31 and antiphosphohistone H3. The angle between a line 
drawn along the long axis of the vessel and the division plane of 
mitotic cells was calculated for 43–63 cells in 11 embryoid bod-
ies for each reVEGF. The majority of the division planes was 
oriented within 75–90° (i.e., close to perpendicular to the long 
axis of the vessel; Fig. 4, D and E).
VEGF111 induces vascularization in vivo
Nude mice (six per group) were injected with matrigel contain-
ing empty plasmid–transfected (control) HEK293 in one fl  ank 
and HEK293 expressing VEGF111, 121, or 165 in the controlat-
eral fl  ank. In addition, three mice were injected with control cells 
in both fl  anks. Tumors were observed at the site of injection in 
nearly all mice: 21/21 in control HEK293, six/six in HEK293/111, 
three/six in HEK293/121, and six/six in HEK293/165. High 
levels of each VEGF mRNA splice variant were found in their 
respective tumors but not in control tumors (Fig. S1, available 
at http://www.jcb.org/cgi/content/full/jcb.200703052/DC1). 
No VEGF121 mRNA was found in the remnant plugs of matrigel 
in the three unresponsive mice. Circulating human VEGF, which 
was measured by ELISA, was detected in the six mice injected 
with HEK293/111 (386 ± 122 pg/ml), in the three responsive 
mice injected with HEK293/121 (411 ± 131 pg/ml), and in the 
six mice injected with HEK293/165 (436 ± 279 pg/ml). None 
was found in mice injected with control HEK293 in both fl  anks.
The tumors displayed different macroscopic aspects ac-
cording to the VEGF isoform expressed by HEK293 cells. The tu-
mor mass and its peritumoral vascularization visualized through 
the skin are delineated by dotted lines in Fig. 5 A. In the control 
and HEK293/121, the tumors remained restricted to the site of 
injection, appearing as a white mass in the control and bluish in the 
121 tumors. In mice injected with HEK293/111 and HEK293/165, 
the tumors appeared largely surrounded by a highly vascularized 
Figure 2.  Expression of VEGF111 in MCF-7 tumors treated with campto-
thecin. Estrogen-supplemented nude mice received a subcutaneous injec-
tion of MCF-7 cells (4 × 10
6 cells) mixed with 100 μl matrigel in both ﬂ  anks. 
After 3 wk, they received a daily intratumoral injection of 50 μl camptothe-
cin (2 mg/ml) or the vehicle alone for 1 and 2 d. Tumors were collected 24 h 
after the last injection, and the VEGF mRNA expression was measured by 
RT-PCR. MWM, molecular weight marker; CPT, camptothecin treatment. 
The asterisk indicates the RT-PCR products of synthetic RNA added to the 
test tubes to monitor reaction efﬁ  ciency.JCB • VOLUME 179 • NUMBER 6 • 2007  1266
Figure 3.  VEGF111 is biologically active in vitro. (A) Expression of reVEGF in HEK293 cells and deglycosylation. HEK293 cells were transformed with 
vectors enabling the expression of VEGF111, 121, and 165. CM containing 20 ng VEGF as measured by ELISA was analyzed by Western blotting before and 
after treatment with N-glycosidase F (PNGase). (B and C) Serum-starved overnight HUVECs, PAEC, PAEC/R1, or PAEC/R2 (expressing VEGF-R1 or -R2) were 
treated with CM of HEK293 cells expressing VEGF111, 121, or 165 or with commercially available reVEGF165 (cVEGF) produced in bacteria (10 ng/ml each) 
or with 10% FCS for 5 min. Untreated cells (−) or cells treated with CM of control HEK293 cells (CM) served as controls. Total and phosphorylated VEGF-R2 
(B) and ERK1/2 (C) were measured by Western blotting. (D) HUVECs labeled with Fluo3-AM were treated with CM of HEK293 cells expressing 10 ng/ml 
of VEGF111, 121, or 165 or CM from control HEK293 cells (CM). The percentage of cells responding by a 20% increase in intracellular free calcium INDUCTION OF VEGF111 BY GENOTOXIC AGENTS • MINEUR ET AL. 1267
zone as judged from the bluish color of the skin. The cyanotic 
skin surface was measured individually, and the mean was 133 ± 
57 mm
2 for the VEGF121 tumors, 258 ± 115 mm
2 for the VEGF165 
tumors, and signifi  cantly larger, 397 ± 102 mm
2, for the VEGF111 
tumors. After dissection (Fig. 5 B), the control tumors and its 
surrounding tissues were indeed poorly vascularized. A dense 
network of vessels had developed in the peritumoral tissue in 
HEK293/111 mice (six/six), whereas the tumor themselves were 
poorly vascularized. In contrast, the 165 tumors (six/six mice) and, 
to a lesser extent, the 121 tumors (three/three mice) where highly 
vascularized, as shown by their reddish appearance, whereas 
the peritumoral tissue was poorly vascularized. 
These observations were confi  rmed by histological analy-
ses (Fig. 5 C). Sections through the tumor and the peritumoral 
tissue were stained for α smooth muscle actin (αSMA). The 
control and the VEGF111 and 121 tumors contained a moderate 
number of vessels delineated by αSMA-positive cells, whereas 
the VEGF165 tumors showed large kystic ectasia containing 
red blood cells and tumoral cells. The peritumoral tissue was 
poorly vascularized in control HEK293 tumors, whereas it con-
tained a very large number of vessels in VEGF111 tumors. Fewer 
but larger size vessels were observed in VEGF121 and 165 peri-
tumoral tissue. This observation was confi  rmed by quantifying 
the number and size of αSMA-positive vessels per millimeter
2 
of peritumoral tissue. The vessel density within the tissue sur-
rounding the tumor (Fig. 5 E) was actually signifi  cantly higher in 
VEGF111 mice (P < 0.01) than in control, VEGF121, or VEGF165 
mice that contained a similar low number of vessels. The mean 
size of these peritumoral vessels (Fig. 5 F) was signifi  cantly 
higher in VEGF121 and VEGF165 mice (2,042 ± 2,537 μm
2 and 
4,505 ± 9,060 μm
2, respectively), whereas it was similar in control 
and VEGF111 mice (740 ± 1,073 μm
2 and 1,042 ± 1,710 μm
2, 
respectively). The level of CD31 mRNA in the tumors expressing 
each isoform of VEGF was signifi  cantly higher than in the con-
trol tumor (Fig. 5 D).
The lateral thoracic vein and afferent vessels draining the 
tumor were signifi  cantly enlarged in mice bearing tumors ex-
pressing the three VEGF isoforms as compared with control 
tumors. Moreover, this enlargement was signifi  cantly higher 
in mice bearing VEGF111 tumors than the two other isoforms 
(Fig. 5 B and Fig. S2, available at http://www.jcb.org/cgi/content/
full/jcb.200703052/DC1).
As an element of interpretation of the in vivo data, clear-
ance of the various reVEGF isoforms was determined after an 
i.v. injection. The half-life was 74 min for VEGF111, 73 min 
for VEGF121, and 55 min for VEGF165 (Fig. S3, available 
at http://www.jcb.org/cgi/content/full/jcb.200703052/DC1). 
Altogether, these results demonstrate that the VEGF111 isoform 
displays potent angiogenic activity both in vitro and in vivo.
reVEGF111 is resistant to proteolytic 
degradation and remains biologically active
The main site of cleavage of VEGF by plasmin has been identi-
fi  ed as Arg110-Ala111 (Keyt et al., 1996) in the sequence encoded 
by exon 5, suggesting that VEGF111 should be resistant to plas-
min. Upon incubation of the reVEGF isoforms with purifi  ed 
plasmin at increasing concentrations for 4 h, both reVEGF121 
and 165 were progressively degraded in fragments with an ap-
parent molecular size of 14–18 kD under reducing conditions, 
which is consistent with the expected size of glycosylated and 
Figure 4.  VEGF111 induces angiogenesis in embryoid bodies. 
Embryoid bodies were formed in the presence of CM from HEK293 
cells expressing VEGF111, 121, or 165 or CM from control 
HEK293 cells (CM). (A) Representative microphotograph of embry-
oid bodies after immunoﬂ  uorescent labeling of CD31. (B) Several 
microphotographs of six embryoid bodies from three independent 
experiments for each treatment were taken at random and ana-
lyzed by ﬁ  ve investigators in double blind, and a score (from 0 to 3, 
where 0 indicates lack of vascular labeling and 3 indicates maxi-
mum labeling) was given to each sample. Statistical analysis was 
performed using a Chi square test. ***, P < 0.0001. (C) CD31 
mRNA level was measured in embryoid bodies by RT-PCR. Statistical 
analysis was performed using a t test. *, P < 0.05; **, P < 0.01. 
(D and E) Embryoid bodies were differentiated in the presence of 
reVEGF111, 121, or 165. The angle between the plane of division 
of endothelial cells and the long axis of the vascular structures was 
analyzed after labeling of the vessels with anti-CD31 (green) and 
the mitotic cells with antiphosphohistone H3 (red) as illustrated 
by the cell in D for two sister cells having divided with a 90° angle. 
The angle of division plane was recorded for 43–63 cells in each 
group of embryoid bodies (n = 11). A scoring of the distribution of 
the angles is shown in E. Error bars represent SD.
concentration was recorded. (E) HUVECs were treated with HEK293 CM containing 10 ng/ml VEGF111 (black circles), 121 (open triangles), or 165 
(black triangles) or CM from control HEK293 cells (open circles). DNA was measured in triplicate wells harvested as a function of time. (F) A modiﬁ  ed 
Boyden chamber assay was used to measure the effect of VEGF111 (black circles), 121 (open triangles), 165 (open squares), and control medium (dotted line) 
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nonglycosylated monomers of VEGF110. In contrast, reVEGF111 
was completely resistant to plasmin (Fig. 6 A). Similar results 
were obtained after incubation with fl  uids collected from hu-
man nonhealing wounds known to be rich in proteases, includ-
ing plasmin. reVEGF121 and 165 were almost completely 
degraded already after a 4-h incubation, whereas reVEGF111 
remained intact even after 24 h (Fig. 6 B). HUVECs were incu-
bated with control CM and CM containing each of the three 
VEGF isoforms, pretreated or not pretreated with plasmin or 
fl  uids from chronic ulcer. As expected, [
3H]thymidine incorpor-
ation was stimulated in cells treated with reVEGF isoforms 
(Fig. 6 C). Pretreatment of reVEGF165 and 121 with plasmin 
(0.32 U) induced a slight but signifi  cant decrease in prolifera-
tive activity (Fig. 6 C), whereas pretreatment with wound fl  uid 
completely abolished it (Fig. 6 D). In contrast, neither plasmin 
nor chronic wound fl  uid affected [
3H]thymidine incorporation 
induced by reVEGF111.
VEGF111 is not induced by hypoxia, 
hypoglycemia, apoptosis, or reactive 
oxygen species but seems to be related to 
DNA damage
Hypoxia, a recognized mechanism able to stimulate VEGF ex-
pression (Stein et al., 1995), was induced by culturing MCF-7 
cells under 1% O2 or mimicked by treatment with cobalt ions. 
Although both treatments induced an overall VEGF mRNA over-
expression, about twofold in agreement with published observa-
tions (Maity et al., 2000), they failed to induce a detectable level 
of VEGF111 (unpublished data). Hypoglycemia, which is also 
known to increase VEGF expression, was induced by culturing 
MCF-7 cells in glucose-free DME compared with DME supple-
mented with 4.5 g/liter glucose. Again, VEGF111 mRNA was 
not detected, whereas the overall VEGF expression was stimu-
lated by twofold.
Beside genotoxicity, UV-B and camptothecin induce non-
genomic effects as the production of reactive oxygen species 
(ROS) and apoptosis (Hattori-Nakakuki et al., 1994). To deci-
pher whether genomic effect, cell death, or oxidative stress 
triggers the expression of VEGF111 mRNA, MCF-7 cells were 
treated by puromycin and H2O2 as inducers of apoptosis and 
ROS, respectively. The Bcl-Xs/Bcl-Xl mRNA ratio monitored in 
parallel progressively increased with H2O2 concentrations to 
reach a concentration of 250 μM, a level similar to that observed 
after treatment with UV-B (Fig. S4, available at http://www.jcb
.org/cgi/content/full/jcb.200703052/DC1). However the level of 
VEGF111 mRNA remained 20–30-fold lower in H2O2-treated 
cells than in the UV-B–treated cells, suggesting that apoptosis and 
ROS do not trigger the splicing mechanism leading to VEGF111 
expression. Similarly, puromycin barely induced VEGF111 ex-
pression while increasing the Bcl-Xs/Bcl-Xl mRNA ratio to a 
level similar to that observed in UV-B. Cells treated with ROS 
inducers FeSO4 (10 μM) or Na2Fe(CN)5NO (80 μM) also failed to 
Figure 5.  VEGF111 induces angiogenesis in vivo. Mice were 
injected with a mixture of matrigel and HEK293 cells expressing 
reVEGF111, 121, or 165 or were transfected with empty vector 
(Cont) and killed after 3 wk. (A) Photographs of one representa-
tive mouse of each group before dissection. Dotted lines delimit 
the surface of the tumor and the peritumoral vascular network 
visible through the skin. (B) Photographs of one representative 
mouse of each group after dissection showing the tumor and 
the peritumoral tissue. Arrows indicate the lateral thoracic veins. 
(C) Histopathological analysis of the tumor and peritumoral tissues. 
Sections were stained with anti-αSMA antibodies and hematoxylin-
eosin. (D) Expression of CD31 mRNA in the tumors: the mRNA 
was measured by RT-PCR in control HEK295 tumors (n = 21) and 
tumors grown from HEK293/111 (n = 6), HEK293/121 (n = 3), 
and HEK293/165 (n = 6). The data were corrected by the 
signals obtained for the 28S rRNA. (E) Number of vessels per 
millimeter squared of peritumoral tissue. The vessels were counted 
on parafﬁ  n sections of control mice (20 sections) and 111 (six 
sections), 121 (three sections), and 165 (six sections) mice. 
(F) Surface of the αSMA-positive vessels in the peritumoral tissue. 
Dots represent individual values, and horizontal bars indicate the 
mean value. *, P < 0.01; **, P < 0.0001 (versus control tumor). 
Statistical analysis was performed using the t test. Error bars 
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express VEGF111 (unpublished data). Together, these data strongly 
suggest that induction of VEGF111 expression by genotoxic 
agents is not related to apoptosis or to oxidative stress. They also 
indicate that the regulation of pre-mRNA splicing that results in 
the expression of VEGF111 and Bcl-Xs are different processes. 
Accordingly, the Bcl-Xs/Bcl-Xl mRNA ratios measured in the 
various cell types after UV irradiation did not correlate with the 
expression of VEGF111 (Table II).
Preliminary data suggest that VEGF111 expression could 
depend on ataxia telangiectasia mutated/ATR (ataxia telangiec-
tasia and Rad3 related) and p53 known to be activated by geno-
toxic agents. Further work is progressing to decipher the signaling 
mechanisms involved in this alternative splicing.
Discussion
VEGF111 is a new splice variant of VEGF-A lacking exons 
5–7. Its expression is induced in several types of cultured cells 
by genotoxic agents such as UV-B, camptothecin, l-mimosin, 
and mitomycin C. UV-B triggers the formation of pyrimidine 
dimers in DNA, whereas camptothecin, l-mimosin, and mito-
mycin C induce double-strand breaks. Surprisingly, γ irradia-
tion, which also leads to double-strand breaks, does not induce 
VEGF111 expression.
Relationship between structure and 
biological properties of VEGF111
The VEGF mRNA variants described up to now contain exons 
1–5 and a combination of exons 6a, 6b, 7, and 8 (Robinson and 
Stringer, 2001; Bates et al., 2002). The VEGF111 encoded by 
exons 1–4 and 8 contain the sequences responsible for binding 
to VEGF-R1 and VEGF-R2, which were located in exons 3 and 4, 
respectively, whereas binding sites for NRP-1, heparin, and ECM 
components encoded by exons 6 and 7 are lacking. Lack of the 
ECM-binding domain of the protein confers to VEGF111 a larger 
bioavailability, which might explain some of our fi  ndings in the 
in vivo experiments that are discussed later. No specifi  c function has 
been ascribed for the short amino acid sequence encoded by exon 8. 
However, its role may be underestimated because VEGF165b 
containing an alternative exon 8 has antiangiogenic properties 
(Bates et al., 2002). It has also been suggested that exon 8 stabi-
lizes VEGF binding to NRP-1 (von Wronski et al., 2006).
Although recombinant human VEGF121 and 165 pro-
duced in HEK293 cells were only partly glycosylated, VEGF111 
was fully glycosylated, as shown by the difference in the elec-
trophoretic pattern before and after treatment with PNGase. 
This suggests that Asn74 is more accessible to the glycosylation 
machinery in VEGF111. Although VEGF glycosylation appears to 
have no major effect on its biological activity, it seems required 
for effi  cient secretion (Peretz et al., 1992; Claffey et al., 1995). 
The new splice variant VEGF111 is indeed effi  ciently secreted 
and is as active as the other known VEGF isoforms.
Houck et al. (1991) reported that VEGF165 and 121, the 
shortest previously described isoform encoded by exons 1–5 and 8, 
as well as VEGF110, a proteolytic fragment obtained after par-
tial digestion by a plasmin-containing sequence encoded by ex-
ons 1–4 and a partial sequence of exon 5, have similar endothelial 
cell mitogenic activity. In agreement with these observations, 
we found that the mitogenic activity of VEGF111 on endo-
thelial cells was similar to that of VEGF121 and slightly less 
effi  cient than VEGF165. The lack of sequences encoded by 
exons 5–7 in VEGF111 and exons 6–7 in VEGF121 might affect 
the positioning of the receptor-binding interfaces in the dimeric 
molecules. Moreover, the absence of the NRP-1–binding site in 
these two isoforms could also be responsible for their slightly 
reduced mitogenic activity (Soker et al., 1997). The phosphory-
lation level of the VEGF-R2 induced by VEGF111 was found to 
be similar to that induced by VEGF121 and slightly lower than 
the activation produced by VEGF165.
The main sites of cleavage of VEGF by plasmin and ma-
trix metalloproteinases were found in the sequence encoded by 
exon 5 (Claffey et al., 1995; Keyt et al., 1996; Lee et al., 2005). 
Figure 6.  VEGF111 is resistant to degradation by plasmin 
and proteases from nonhealing chronic wound ﬂ  uid. 
(A and B) CM from HEK293 containing 20 ng reVEGF165, 
121, and 111 were treated at 37°C with the indicated 
concentrations of plasmin for 4 h (A) or 10 μl of ﬂ  uid 
collected from a chronic wound for the indicated times 
(B). The products were analyzed by Western blotting. 
(C and D) Cultures of HUVECs were treated with HEK293 
cell CM containing 2 ng/ml VEGF111, 121, or 165, 
CM from control HEK293 (CM), or 2 ng/ml of commer-
cial reVEGF165 (cVEGF) produced in bacteria either un-
treated or pretreated with 0.32 U plasmin for 4 h (C) or 
ﬂ  uids collected from a chronic ulcer for 24 h (D). After 
48 h, the cells were incubated with [
3H]thymidine for 18 h, 
and TCA-precipitable radioactivity was measured. Statistics 
were performed using the analysis of variance test followed 
by the Tukey-Kramer test. *, P < 0.05; **, P < 0.001. 
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As expected on the basis of the lack of exon 5, VEGF111 is not 
sensitive to degradation by plasmin in conditions that cleave 
VEGF121 and165 isoforms primarily between residues 110 and 
111, producing VEGF110 homodimers. Accordingly, the mito-
genic potential of VEGF111 is unaffected by plasmin treatment, 
whereas that of VEGF121 and 165 is reduced. Fluid collected 
from a nonhealing chronic wound was used as a source of proteo-
lytic enzymes found in cutaneous impaired healing conditions. 
Incubation of VEGF165 and 121 results in their complete proteol-
ysis and a total loss of their mitogenic activity, whereas VEGF111 
is completely resistant to degradation and retains its full biologi-
cal properties. A similar degradation of VEGF165 by fl  uids from 
chronic ulcers was reported by Lauer et al. (2000). It was pre-
vented by mutating the Arg110 and Ala111 plasmin cleavage site 
(Lauer et al., 2002), further suggesting that the cleavage of VEGF 
within exon 5 unmasks proteolytic sites that are cryptic otherwise.
VEGF111, phosphorylated VEGF-R2, and ERK1/2 in-
duced calcium transient and stimulated HUVEC proliferation 
similarly to the 121 and 165 isoforms. Although we have no 
direct evidence of the binding of VEGF111 to VEGF-R1, two 
arguments are in favor of VEGF111 signaling via this receptor. 
The fi  rst is the induction of ERK1/2 phosphorylation by VEGF111 
in the PAEC/R1 cells similarly to the VEGF121 and 165 isoforms. 
The second comes from the results of the oriented endothelial 
cell division in the embryoid bodies assay. According to Zeng 
et al. (2007), the preferential orientation perpendicular to the long 
axis of the vessel, as we observed in embryoid bodies differenti-
ated by VEGF111, 121, and 165, is determined by Flt-1 because 
embyonic stem Flt-1
−/− loses this behavior. A controversial argu-
ment is the lack of induction by VEGF111 of monocyte chemo-
tactic migration. Further work is needed to clarify the issue.
Although VEGF111 displays biological activities in vitro 
close to those of VEGF121 and 165, the three isoforms elicited 
a different pattern of the neovasculature in and around the tumors 
produced by the injection of transfected HEK293 with their 
respective cDNA. VEGF111-expressing tumors were macro-
scopically pale and exhibited moderate intratumoral vascular-
ization in high contrast with VEGF165-expressing tumors that 
were highly vascularized and contained large blood lacunae. 
No or little infl  ammatory infi  ltrate was observed in any type of 
tumor. A most striking feature was the presence in the peri-
tumoral tissue of an extensively developed network of small size 
vessels around VEGF111-expressing tumors, whereas the vessels 
in the peritumoral area of VEGF121 and 165 tumors were less 
numerous but of larger size. These fi  ndings are in agreement with 
those of Lee et al. (2005), who reported that tissues adjacent to 
xenograft tumors expressing a protease-resistant mouse VEGF 
(VEGF∆108–118, corresponding to VEGF164 but lacking most 
of the sequence encoded by exon 5) had smaller vessels at higher 
density than tumors expressing wild-type VEGF164. The develop-
ment of a high density vascular network in the adjacent tissue of 
VEGF111-expressing tumors may be correlated with its reduced 
potential for ECM binding. However, the diffusible VEGF121 
that shares a similar feature and has a similar half-life did not 
induce the same vascular organization. The widespread peritu-
moral vascular network in VEGF111 mice may also contribute 
to enlargement of the draining thoracic vein.
As the HEK293 cells transfected with the cDNA of either 
isoform proliferate and migrate at the same rate, at least in vitro, 
and the mRNA level of each isoform is similar in the three types 
of tumors (Fig. S1), the differences observed in the tumoral and 
peritumoral vascular network are likely linked to the diffusible 
properties and/or possibly to the resistance to proteolysis of the 
various isoforms. The mechanisms that regulate these different 
patterns require additional investigations.
VEGF111, a promising therapeutic agent?
VEGF111 mRNA is absent from all healthy human or murine 
tissues that we tested. We also failed to detect it in mouse skin 
after UV-B irradiation. This is not surprising, as its expression in 
UV-B–treated human skin fi  broblasts and keratinocytes in vitro is 
very low. In contrast, it was induced in MCF-7 tumors upon treat-
ment with camptothecin. The potential induction of VEGF111 by 
chemotherapy might be an adverse side effect that could contrib-
ute to the acquisition of drug resistance. The fi  nding that VEGF111 
expression by xenografts of HEK293 cells surpasses VEGF121 and 
165 in inducing the formation of a large array of vessels around 
the tumor supports this hypothesis, which needs further experi-
mental and clinical investigations to be fi  rmly established.
Defective vascularization and ischemia is a signifi  cant medi-
cal problem in many disciplines, including cardiovascular diseases 
and wound healing. VEGF-A plays a pivotal role in the angio-
genic process during tissue repair. In chronic wounds, although 
increased VEGF mRNA was detected in the epidermis (Brown 
et al., 1992), the proteolytic environment and mainly serine pro-
teases such as plasmin lead to VEGF degradation (Lauer et al., 
2000; and unpublished data) and impaired vascularization. 
Mutation of the plasmin cleavage site Arg110/Ala111 in VEGF165 
(Lauer et al., 2002) generated a proteolysis-resistant variant that 
induced an improved healing response in the db/db mouse (Roth 
et al., 2006). The potent angiogenic properties of VEGF111 and 
its remarkable resistance to proteolysis make it an interesting 
alternative candidate for therapeutic use in ischemic diseases. 
This is presently under investigation.
Materials and methods
Cell culture
Cells were cultured in DME containing 10% FCS (Cambrex), 2 mM gluta-
mine, 50 μg/ml ascorbic acid, penicillin, and streptomycin except other-
wise indicated. MO59K was cultured in DME/Nut Mix F-12 (Invitrogen) 
with 10% FCS, 2 mM glutamine, nonessential amino acids (Invitrogen), 
penicillin, and streptomycin; HEK293 cells were cultured in DME containing 
10% FCS, nonessential amino acids, penicillin, streptomycin, 2 mg/liter 
fungizone, and 40 mg/liter gentamycin. PAECs were cultured in Ham F-12 
(Invitrogen) with 10% FCS, gentamycin, penicillin, streptomycin, and fungi-
zone, and HCT116 cells were cultured in MacKoy’s medium (Cambrex) 
containing 10% FCS, penicillin, and streptomycin. Primary human keratino-
cytes were cultured in KGM-2 (Cambrex), and HUVECs were cultured in 
MCDB-131 medium (Invitrogen) complemented with 20% FCS, 2 mM gluta-
mine, 5.8 U/ml heparin (Sigma-Aldrich), penicillin, and streptomycin on 
a coat of 0.2% gelatin. All cultures were kept at 37°C under 5% CO2 except 
otherwise indicated. Monocytes were isolated from buffy coats obtained 
from healthy donors (Transfusion Center, Liège, Belgium) as described pre-
viously (Stadler et al., 2007).
Chemicals
reVEGF165, plasmin, camptothecin, mimosin, FeSO4, and Na2Fe(CN)5NO 
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mitomycin C was purchased from Kyowa Hakko Kogyo, hygromycin was 
obtained from Invitrogen, and irinotecan was purchased from Aventis.
Antibodies, Western blotting, immunohistochemistry, and ELISA
The following antibodies were used: anti-ERK1/2 (rabbit polyclonal), antiphos-
pho-ERK1/2 (monoclonal), and FITC-conjugated anti-αSMA were obtained 
from Sigma-Aldrich; anti–VEGF-R2 (rabbit polyclonal) and anti-VEGF (rabbit 
polyclonal) were purchased from Santa Cruz Biotechnology, Inc.; antiphos-
pho–VEGF-R2 (rabbit polyclonal) was purchased from EMD; polyclonal rabbit 
antiphosphohistone H3 (Ser10) was obtained from Millipore; rat anti–mouse 
CD31 was purchased from BD Biosciences; sheep anti-FITC antibodies conju-
gated to HRP were purchased from Roche; secondary antibodies conjugated 
with biotin, HRP, or streptavidin/FITC were obtained from Dako; and FITC-
  labeled donkey anti–rat antibodies and rhodamine-labeled donkey anti–rabbit 
antibodies were purchased from Jackson ImmunoResearch Laboratories.
Proteins were separated by SDS-PAGE and transferred onto polyvinyl-
idene diﬂ  uoride transfer membranes (PerkinElmer) by electroblotting. Mem-
branes were blocked by nonfat dry milk (3% in PBS-Tween buffer) and 
probed with primary antibodies revealed by HRP-conjugated secondary 
  antibodies. Signals were detected by chemiluminescence using an ECL West-
ern Blotting Analysis System (Thermo Fisher Scientiﬁ  c) and x-ray ﬁ  lm exposure 
and were quantiﬁ  ed using a Fluor-S MultiImager (Bio-Rad Laboratories).
Tissue samples were ﬁ  xed in formaldehyde and embedded in parafﬁ  n, 
and sections of 5 μm were successively reacted with anti-αSMA antibodies 
conjugated with FITC and anti-FITC conjugated with HRP and were stained 
with DAB, hematoxylin, and eosin. The samples were mounted with Aqua 
PolyMount (Polysciences Inc.) and visualized at room temperature using an 
inverted ﬂ  uorescent microscope (Axiovert 25; Carl Zeiss, Inc.) with a 63× 
NA 1.25 objective magniﬁ  cation, camera (Axiocam; Carl Zeiss, Inc.), and 
KS400 acquisition software (Carl Zeiss, Inc.). Human VEGF was measured 
in the CM of cultured cells or in blood samples by ELISA (R&D Systems) as 
described by the manufacturer.
RNA puriﬁ  cation
Total RNA was puriﬁ  ed from cell culture using a High Pure RNA Isolation kit 
(Roche) and from early mouse embryos (days 6–9) using a High Pure RNA 
Tissue kit (Roche) after grinding in lysis solution with a Dounce homogenizer. 
Tissues from older mouse embryos and adult mouse or human tissues were 
crushed in liquid N2 (Dismembrator; Braun Biotech International), and RNA 
was collected by cesium chloride ﬂ  oatation (Chirgwin et al., 1979) or by 
using the High Pure RNA Tissue kit.
RT-PCR ampliﬁ  cation
RT-PCR ampliﬁ   cations were performed using the GeneAmp PCR System 
2400 or 9800 (PerkinElmer) and GeneAmp Thermostable rTth Reverse Tran-
scriptase RNA PCR kit (PerkinElmer), 10 ng of total RNA, and the different 
pairs of primers (5 pmol each; see Table I). For ampliﬁ  cation of the VEGF 
isoforms mRNA and 28S ribosomal RNA (rRNA), a known copy number of 
a synthetic standard RNA was included in each sample to monitor the reac-
tion efﬁ  ciency (Hajitou et al., 2001; Lambert et al., 2001). Bcl-X and CD31 
mRNA were measured using the same conditions as the 28S rRNA. For Bcl-X 
mRNA ampliﬁ  cation, the primers chosen on exons 1 and 3 ampliﬁ  ed both 
Bcl-Xs and Bcl-Xl isoforms. For speciﬁ  c detection of the VEGF111 isoform, 
mRNA was reverse transcribed using oligodT (Eurogentec) and Superscript II 
(Invitrogen) as described by the manufacturer. Reverse transcription at 42°C 
for 50 min was followed by denaturation of the enzyme at 70°C for 15 min. 
40 ng VEGF111 cDNA was ampliﬁ  ed by PCR, the primers P1 and P5 (Table I), 
and Taq polymerase (Takara). Conditions for PCR ampliﬁ  cation were 94°C 
for 15 s, 60°C for 20 s, and 72°C for 10 s.
Irradiation with UV-B light and 𝗄 rays
15 × 10
3 cells/cm
2 were seeded for 24 h. Culture medium was replaced 
by a thin layer of phenol red–free DME, and cells were irradiated in open 
dishes with UV (30 mJ/cm
2 except otherwise indicated) using two lamps 
(TL 20W/12; Philips) in the hood. The UV light spectrum was 90% UV-B 
and 10% UV-A, whereas no UV-C was detected as measured by a radio-
meter (UVX; UVP Inc.). After irradiation, the phenol red–free DME was re-
placed by fresh culture medium. Mice were irradiated by using the same 
equipment after a short anesthesia. Cells in DME containing 25 mM Hepes, 
pH 7.25, and mice were γ irradiated in an exactor (Gammacell 40; MDS 
Analytical Technologies) at 1.15 Gy/min.
Characterization of the VEGF111 splice variant mRNA
VEGF mRNA from UV-irradiated HaCat cells were RT-PCR ampliﬁ  ed using 
the P1 and P2 primers (Table I). The VEGF111-speciﬁ  c product was extracted 
from the acrylamide gel and sequenced using a Thermo-sequenase radio-
labeled terminator cycle sequence kit (GE Healthcare). Full-length VEGF111 
cDNA was obtained by RT-PCR ampliﬁ  cation using primers P3 and P4 
(Table I) and was sequenced.
Production of reVEGF
RNA puriﬁ  ed from UV-irradiated HaCat cells was reverse transcribed using 
SuperScriptII and an oligodT primer. The complete coding sequences of 
VEGF111, 121, and 165 were ampliﬁ   ed with Pwo DNA polymerase 
(Roche) using P3 (having an NotI restriction site sequence at its 5′ end) and 
P4 (having an NheI restriction site sequence at its 5′ end). After restriction 
with NotI–NheI and puriﬁ  cation of the cDNA of interest, the PCR products 
were ligated (Ligation kit version II; Takara) between the NotI and NheI 
sites of a pCEP4 vector (Invitrogen) containing a home-modiﬁ  ed multiple 
cloning site (Colige et al., 2005). Plasmids were ampliﬁ  ed in XL10-Gold 
ultracompetent bacteria (Stratagene) and prepared using the Plasmid Mini-
prep kit (Bio-Rad Laboratories). HEK293 cells were transfected by 1–2 μg 
plasmid using FuGene 6 (Roche), and transformed cells were selected by 
100 mg/liter hygromycin for 2–3 wk.
Cell multiplication
15,000 HUVECs were seeded in gelatin-coated multiwells in the presence 
of MCDB-131 supplemented with 20% FCS. After 3 h, the medium was re-
placed by fresh medium with or without VEGF and renewed every 2 d. 
Cells were collected at various times, and the DNA was measured by 
  ﬂ  uorimetry using a SpectraMax Gemini XS apparatus (MDS Analytical 
Technologies) after labeling with bis-benzimide. In some experiments, 1 μM 
[
3H]thymidine (2.5 Ci/mol; PerkinElmer) was added to cell cultures at day 2, 
and the TCA-precipitable radioactivity was measured after 18 h.
Cell migration
Chemotactic migration assays of PAEC/R2 and human monocytes were 
performed in a modiﬁ  ed Boyden chamber assay as previously described 
(Waltenberger et al., 1994; Stadler et al., 2007).
Intracellular calcium measurement
Measurements of intracellular free calcium transients induced by VEGF111, 
121, and 165 in HUVECs were performed as previously described (Mineur 
et al., 2005).
N-deglycosylation of VEGF
CM of HEK293 cells expressing VEGF165, 121, or 111 or from control cells 
containing the empty plasmid were treated with PNGase F (N-glycosidase F; 
New England Biolabs, Inc.) as described by the manufacturer. The electro-
phoretic pattern of the various VEGF isoforms before and after enzymatic 
treatment was determined by SDS-PAGE and Western blotting.
In vitro angiogenesis
Embryoid bodies were formed as previously described (Deroanne et al., 
2002). In brief, undifferentiated embryonic stem CGR8 cells were aggre-
gated for 4 d in a 20-μl drop of DME supplemented with 10% FCS, 0.1 mM 
nonessential amino acids, 0.1 mM β-mercaptoethanol, and 5 ng/ml of the 
various reVEGF isoforms and were further kept in culture on gelatin-coated 
coverslips for 6 d in the same medium (n = 6 for each isoform). For immuno-
histochemistry, embryoid bodies were ﬁ  xed in methanol and incubated with 
rat anti–mouse CD31 antibodies, biotin-conjugated anti–rat IgG, and strep-
tavidin/FITC. The CD31 mRNA was measured by RT-PCR. A similar procedure 
was used (n = 11 embryoid bodies for each isoform) to determine the orien-
tation plane of mitotic endothelial cells as described previously (Zeng et al., 
2007) by a double immunostaining using anti-CD31 as above, antiphospho-
histone H3, and rhodamine-labeled secondary antibodies. Samples were 
mounted in Aqua PolyMount. Immunostaining was observed at room tempera-
ture by inverted confocal microscopy (TSP2; Leica) with an objective magni-
ﬁ  cation of 10× NA 0.3 and confocal acquisition software (Leica) or by an 
inverted microscope (Axiovert 25; Carl Zeiss, Inc.).
In vivo angiogenesis
HEK293 cells transfected with the empty vector or expressing human 
reVEGF111, 121, or 165 were mixed (2 × 10
6 cells) with 200 μl matrigel 
depleted in growth factors (Becton Dickinson) and injected subcutaneously 
in the ﬂ  anks of nude mice (6-wk-old Swiss Nu/Nu). After 3 wk, mice were 
killed according to the ethical policy of our institute. Blood was collected by 
heart puncture. Tumors and the surrounding tissues were inspected and dis-
sected. Half of each specimen was used for morphological analysis, and the 
other half was used for RNA extraction.JCB • VOLUME 179 • NUMBER 6 • 2007  1272
Experimental chemotherapy
Nude mice supplemented with oestrogens (SE-121 17 β-Estradiol 1.7 mg/
pellet 60-d release; Innovative Research of America) received a subcutane-
ous injection of 4× 10
6 MCF-7 cells mixed with 100 μl matrigel on both 
ﬂ  anks according to a previously described procedure (Sounni et al., 2002). 
After 3 wk, mice were treated by a daily dose of 50 mg/Kg irinotecan or 
10 mg/kg camptothecin, an intratumoral injection of 50 μl camptothecin 
(2 mg/ml), or the vehicle alone for 1, 2, and 3 d and were killed 24 h after 
the last injection. The tumors as well as various organs and tissues were 
collected. VEGF111 mRNA was detected by RT-PCR.
Online supplemental material
Fig. S1 illustrates the expression of VEGF mRNA in tumors obtained after in-
jection in nude mice of HEK293 cells expressing the various VEGF isoforms. 
Fig. S2 shows the diameter of the lateral thoracic vein in mice bearing 
tumors obtained after injection of HEK293 cells expressing the various VEGF 
isoforms. Fig. S3 gives the blood concentration of the various VEGF isoforms 
as a function of time after injection in mice. Fig. S4 illustrates the expression 
of VEGF111 mRNA and the Bcl-Xs/Bcl-Xl ratio in MCF-7 cells treated with 
UV-B, puromycin, or H2O2. Online supplemental material is available at 
http://www.jcb.org/cgi/content/full/jcb.200703052/DC1.
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